protagenic therapeutics is a biotechnology company located in 1625th ave, new york, new york, united states.
Company profile
Ticker
PTIX, PTIXW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Atrinsic, Inc., MILLBROOK PRESS INC, MPLC, Inc., NEW MOTION, INC.
SEC CIK
Corporate docs
Subsidiaries
Protagenic Therapuetics Canada ...
IRS number
61390025
PTIX stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
23 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
21 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEF 14A
Definitive proxy
2 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
17 Apr 23
Latest ownership filings
4
TIMOTHY R WRIGHT
1 Apr 24
4
Robert Benjamin Stein
29 Mar 24
4
Khalil Barrage
29 Mar 24
4
Jennifer Buell
29 Mar 24
4
GARO H ARMEN
29 Mar 24
4
Brian Corvese
29 Mar 24
4
Alexander K. Arrow
29 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Alexander K. Arrow
13 Oct 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
2.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 160.45 mm |
Total shares | 97.20 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 32.95 k | $66.89 mm |
Geode Capital Management | 25.15 k | $51.80 mm |
FNY Investment Advisers | 18.75 k | $38.00 k |
STT State Street | 13.81 k | $28.45 mm |
Tower Research Capital | 3.75 k | $7.60 mm |
Advisor | 2.76 k | $5.61 mm |
WFC Wells Fargo & Co. | 24.00 | $49.00 k |
BAC Bank Of America | 1.00 | $2.00 k |
MS Morgan Stanley | 1.00 | $2.00 k |
CWM | 1.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Robert Benjamin Stein | PTIX Common stock Options PTIX Common Stock, Par Value $0.0001 | Grant | Acquire A | No | No | 1.74 | 75,000 | 130.50 k | 75,000 |
25 Mar 24 | Khalil Barrage | PTIX Common stock Options PTIX common stock, Par Value $0.0001 | Grant | Acquire A | No | No | 1.74 | 22,500 | 39.15 k | 22,500 |
25 Mar 24 | Buell Jennifer | PTIX Common stock Options PTIX Common Stock, Par Value $0.0001 | Grant | Acquire A | No | No | 1.74 | 75,000 | 130.50 k | 75,000 |
25 Mar 24 | Armen Garo H | PTIX Common stock Options PTIX Common Stock, Par Value $0.0001 | Grant | Acquire A | No | No | 1.74 | 250,000 | 435.00 k | 250,000 |
25 Mar 24 | Corvese Brian | PTIX Common stock Options PTIX Common Stock, Par Value $0.0001 | Grant | Acquire A | No | No | 1.74 | 43,750 | 76.13 k | 43,750 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
25 Apr 24
Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024
17 Apr 24
Protagenic Therapeutics Q4 EPS $(0.38) Down From $(0.14) YoY
2 Apr 24
Earnings Scheduled For April 1, 2024
1 Apr 24
Protagenic Therapeutics Successfully Concludes Third Cohort In Single Dose Portion Of Phase 1 Trial For Stress-Related Neuropsychiatric Disorders
27 Mar 24
Press releases
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
17 Apr 24
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
1 Apr 24
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
27 Mar 24
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
25 Mar 24
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
21 Mar 24